Effect of once-daily generic ciclesonide on exhaled nitric oxide in atopic children with persistent asthma

Mallol, Javier; Aguirre, Viviana; Gallardo, Alejandro; Cortez, E.; Sanchez, Carlos E.; Riquelme, Carlos; Córdova, Pablo; Martinez, M.C.; Galindo, A. Segura

doi:10.1016/j.aller.2015.01.011

Cited by 4 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…94 In a mixed age population, treatment decisions made in an office visit based on a single FeNO test in 50 asthmatic patients led to change in therapy in a small proportion of patients (augmentation in 20% and reduction in 16%). 142 These studies were overall at moderate to high risk of bias.…”

Section: Observational Studiesmentioning

confidence: 99%

“…143 In a mixed-age population, treatment decisions made in a single office visit based on a single FeNO test were estimated to reduce cost by $629 per patient per year. 142 Lastly, a cost-effectiveness analysis model evaluated adding FeNO monitoring to asthma management over a 1-year period. The results showed that adding FeNO to standard asthma care saved €62.53 per patient-year in the adult population and improved quality-adjusted life years by 0.026 per patient-year.…”

Section: Cost and Utilization Datamentioning

confidence: 99%

See 1 more Smart Citation

The Clinical Utility of Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management

Wang¹,

Pianosi²,

Keogh³

et al. 2017

View full text Add to dashboard Cite

Section: Observational Studiesmentioning

confidence: 99%

Section: Cost and Utilization Datamentioning

confidence: 99%

The Clinical Utility of Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management

Wang¹,

Pianosi²,

Keogh³

et al. 2017

View full text Add to dashboard Cite

“…Ciclesonide, licensed from age 4 years in the US and from age 12 years in Europe, is a pro-drug activated by esterases within the lung to form the active compound (des-ciclesonide). The possibility of a single daily administration, and evidence supporting its efficacy in improving asthma control and in reducing airway inflammation make this steroid a valid option as asthma controller therapy (43). Nonetheless, given the lack of relevant differences in the efficacy of ciclesonide vs. fluticasone or budesonide, long-term superiority trials are needed to identify the usefulness and safety of ciclesonide compared to other ICS (44).…”

Section: New Inhaled Corticosteroidsmentioning

confidence: 99%

New Drugs for Pediatric Asthma

2019

View full text Add to dashboard Cite

Asthma is the most common chronic disease in children. As suggested by international guidelines, the main goals of asthma treatment are symptoms control and lung function preservation, through a stepwise and control-based approach. The first line therapy based on inhaled corticosteroids may fail to reach control in more than one third of patients, especially adolescents, and in these lung function and quality of life may progressively worsen. Treatment with omalizumab, the first anti-immunoglobulin E recombinant humanized monoclonal antibody, has been definitely approved in pediatric uncontrolled asthma. In this review, we discuss the mechanisms and potential roles of emerging therapies for pediatric severe asthma. Novel biologic drugs (i.e., dupilumab, mepolizumab, reslizumab, and benralizumab) seem to be promising in reducing annual exacerbation rates and steroid-use in glucocorticoid-dependent cases, but available data are few and limited to adolescents and adults. Evidences on the use of the muscarinic antagonist tiotropium as controller medication in pediatric settings are progressively growing, sustaining an application as asthma maintenance treatment in children aged >6 years and in preschool children with persistent asthmatic symptoms, but well powered trials are needed to confirm its safety and efficacy. New inhaled corticosteroids (i.e., ciclesonide and mometasone) are effective as once-daily controller therapy, but long-term studies in the different pediatric ages are needed to compare effectiveness and safety to usual treatments. At present, the role of macrolides in pediatric severe asthma is controversial and their administration is not recommended routinely, but may be considered in children with neutrophilic asthma for reducing daily oral steroids administration and improving lung function. Despite the availability of several novel therapeutic strategies for uncontrolled asthma, future trials targeted at specific pediatric age subgroups are needed to support evidences of safety and efficacy also in children.

show abstract

Management of Medication Side Effects and Complications

Selby

Fleming

2019

Severe Asthma in Children and Adolescents

View full text Add to dashboard Cite

Effect of once-daily generic ciclesonide on exhaled nitric oxide in atopic children with persistent asthma

Abstract: Once-daily generic ciclesonide (80 μg or 160 μg), for 12 weeks, is effective to improve airway inflammation and asthma control in atopic children with persistent asthma.

Cited by 4 publications

References 36 publications

The Clinical Utility of Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management

The Clinical Utility of Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management

New Drugs for Pediatric Asthma

Management of Medication Side Effects and Complications

Contact Info

Product

Resources

About